|
KR20200128026A
|
|
Fusion protein constructs comprising anti-MUC1 antibody and IL-15
|
|
CN111315776A
|
|
PD-L1 and TA-MUC1 antibodies
|
|
WO2018178123A1
|
|
BISPECIFIC MUC-1 x PD-L1 ANTIBODIES
|
|
CN110382538A
|
|
In conjunction with the multi-specificity antibody construct of MUC1 and CD3
|
|
WO2018178046A1
|
|
Humanized anti-cd40 antibodies
|
|
CN110177807A
|
|
Use the anticancer therapy of anti-MUC1 antibody and ErbB inhibitor
|
|
WO2018096078A1
|
|
Serum-free cultivation of progenitor dendritic cells
|
|
US2019185848A1
|
|
Means and methods for modifying multiple alleles
|
|
WO2017162733A1
|
|
Iga antibodies with enhanced stability
|
|
CN108348465A
|
|
The mammal follicle-stimulating hormone (FSH) composition of stability with raising
|
|
WO2017025566A1
|
|
Improved recombinant factor vii
|
|
WO2017029129A1
|
|
Heteromers with enzymatic activity
|
|
CN108350060A
|
|
Include the different aggressiveness of antibody domain fused protein
|
|
WO2016207328A1
|
|
PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
|
|
WO2016198499A1
|
|
IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
|
|
BR112017023624A2
|
|
Small-scale culture method for suspension cells
|
|
BR112017018538A2
|
|
eukaryotic expression vectors comprising regulatory elements of globin gene clusters
|
|
BR112016023668A2
|
|
Ovarian hyperstimulation controlled with improved recombinant human follicle stimulation hormone
|
|
LU92659A1
|
|
Glycooptimized antibody drug conjugates
|
|
WO2015086723A2
|
|
Glycosylated glycophorin peptides
|
